Healthcare

Heart Failure Drugs Market

By Segment, By Region, And Segment Forecasts, 2016 – 2025

Vertical: HealthcareBase Year: 201811 Sections

Executive Summary

Heart Failure Drugs Market — Snapshot

  • Market Size (2016)

    2016

    $3.56B

  • Projected (2025)

    2025

    $13.07B

  • CAGR (2016–2025)

    15.5%

    15.5%
  • Key Players

    108+

Overview

Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to the body’s need for blood and oxygen. This results in fatigue and shortness of breath and sometimes results in a cough. Due to this, everyday activities such as walking, climbing stairs, or carrying heavy weight becomes very difficult.

Factors such as rising cases of cardiovascular disorders, increasing geriatric population, and the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure are driving the market growth. Additionally, a strong pipeline and product approvals are also driving the market growth. However, serious side-effects hamper the growth of the market.

Key Insight

The Heart Failure Drugs Market market is projected to grow at a CAGR of 15.5% from 2016 to 2025.

Market Performance Trend

Historical performance and future projections (2020–2030, USD Billion)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Scope & Coverage

What this report covers

  • Geographic Coverage: This analysis covers 5 regions: Middle East and Africa, North America, Asia Pacific, Europe, South America.
  • Market Segmentation: The market is analyzed across 6 segments: Angiotensin Receptor Neprilysin Inhibitors, Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, Diuretics, Others. Forecasts are provided for each segment from 2016 to 2025.
  • Competitive Landscape: 108 leading companies are profiled, covering market positioning, strategies, and recent developments.

Market Size (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Overview

Heart Failure Drugs Market — Growth Trajectory

Scope of the Study

The scope of the global heart failure drugs market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on type, end user, and region.

Research Objective

To provide a comprehensive analysis of the global heart failure drugs market and its sub-segments, thereby providing a detailed structure of the industry To provide detailed insights into factors driving and restraining the growth of the global heart failure drugs marketTo estimate the market size of the global heart failure drugs market where 2016 to 2017 would be the historic period, 2018 shall be the base year, and 2019 to 2025 will be the forecast period for the studyTo provide region-wise market value analysis for various segments of the global heart failure drugs marketTo provide strategic profiling of key companies (manufacturers and distributors) present across the globe and comprehensively analyze their competitiveness/competitive landscape in this marketTo provide a distribution chain analysis/value chain for the global heart failure drugs market

Heart Failure Drugs Market — Growth Trajectory

Angiotensin Receptor Neprilysin Inhibitors
Angiotensin Receptor Blockers

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Size Trend (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Dimensions

How this market is segmented

  • Type Type is broken down into: Angiotensin Receptor Neprilysin Inhibitors, Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, Diuretics, Others.
  • End User End User is broken down into: Hospitals, Speciality Centers, End User_Others.

Geographic Analysis

Regional market breakdown

  • Middle East and Africa Middle East and Africa market size reached $370.04M in 2016 and is projected to reach $932.87M by 2025, growing at a CAGR of 10.8%.
  • North America North America market size reached $913.62M in 2016 and is projected to reach $3.63B by 2025, growing at a CAGR of 16.6%.
  • Asia Pacific Asia Pacific market size reached $911.20M in 2016 and is projected to reach $3.49B by 2025, growing at a CAGR of 16.1%.
  • Europe Europe market size reached $1.06B in 2016 and is projected to reach $3.98B by 2025, growing at a CAGR of 15.9%.
  • South America South America market size reached $312.72M in 2016 and is projected to reach $1.03B by 2025, growing at a CAGR of 14.1%.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Research Methodology

Heart Failure Drugs Market — How We Researched This Market

This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.

  • Base Year

    2018

  • Historical Period

    2016 – 2018

  • Forecast Period

    2018 – 2025

  • Primary Interviews

    150+

Research Process

Historical data (2016–2018) and forecast period (2018–2025)

1

Problem Definition

  • Market scoping
  • Objective setting
  • Framework design
2

Secondary Research

  • Literature review
  • Data mining
  • Trend analysis
3

Primary Research

  • Expert interviews
  • Field visits
  • Surveys
4

Data Analysis

  • Quantitative modeling
  • Statistical testing
  • Validation
5

Insights & Reporting

  • Synthesis
  • Recommendations
  • Visualization

Research Depth

Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.

Historical vs. Forecast Data

Historical (observed)
Forecast (modelled)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Competitive Landscape & Porter's Five Forces

Heart Failure Drugs Market — Competitive Analysis

Threat of New Entrants

The threat of new entrants is high in the global heart failure drugs market. The threat of new entrants is high due to the strong pipeline and rising recent product launches. Major players such as AstraZeneca, Merck Sharp & Dohme Corp., and Bayer are involved in developing heart failure specific drugs such as AZD4831, Vericiguat, and Neladenoson bialanate and are aiming to launch the products during the forecast period of 2019 to 2025.

Bargaining Power of Suppliers

In the global heart failure drugs market, suppliers are raw materials manufacturers for drug manufacturing companies. The bargaining power of suppliers is low as there is a high number of suppliers in the heart failure drugs market. Additionally, the switching cost is low as no supplier can influence the prices and exercise control in the industry, which makes the bargaining power low.

Threat of Substitutes

The threat of substitutes in the global heart failure drugs market is low to medium because of the presence of surgeries. But, the high adoption of these drugs by physicians and brand loyalty restrict the threat by the substitutes. Also, the low to medium degree of switching costs may minimize the threat of substitutes.

Bargaining Power of Buyers

The bargaining power of buyers is moderate in the global heart failure drugs market. The presence of buyers in the market is growing due to the increasing awareness about the different products, along with the rising prevalence of heart failure. Additionally, the presence of providers is also increasing, which makes the bargaining power of buyers moderate due to the low switching costs.

Intensity of Rivalry

The degree of competition in the global heart failure drugs market is low as of now. However, it will witness a high degree of competition in the near future. The restrained degree of product and service differentiation among existing players increases the intensity of rivalry in the market. Heart failure drugs provider companies are trying to provide cost-effective services to make them more affordable. To overcome the competition, drug and device manufacturing players are engaged in developing a process to lower their manufacturing costs.

Quantitative Analysis

Regional Breakdown

Regional market breakdown for Heart Failure Drugs Market.

Regional Market Size (USD Mn)

Market estimates by geography (2025)

USD Mn

InsightEurope leads with $3.98B by 2025, while North America is projected to grow fastest at a 16.6% CAGR.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Regional Market Data

REGION201620182025CAGRSHARE
Middle East and Africa$370.04M$568.68M$932.87M10.8%7%
North America$913.62M$1.77B$3.63B16.6%28%
Asia Pacific$911.20M$1.73B$3.49B16.1%27%
Europe$1.06B$1.99B$3.98B15.9%30%
South America$312.72M$548.51M$1.03B14.1%8%
Total$3.56B$6.62B$13.07B15.5%100%

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Segment Revenue (2025)

Angiotensin Receptor Neprilysin Inhibitors
Angiotensin Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Beta Blockers
Diuretics
Others
01262252437855047

Segment Market Share

  • Angiotensin Receptor Neprilysin Inhibitors35%
  • Angiotensin Receptor Blockers20%
  • Angiotensin-Converting Enzyme Inhibitors16%
  • Beta Blockers13%
  • Diuretics10%
  • Others6%

Total Market Size

$13.07B

Market by Segment (2025)

APPLICATIONREVENUE ($B)GROWTH RATEMARKET PENETRATION
Angiotensin Receptor Neprilysin Inhibitors$4.59B15.5%
85%
Angiotensin Receptor Blockers$2.58B15.5%
73%
Angiotensin-Converting Enzyme Inhibitors$2.07B15.5%
77%
Beta Blockers$1.75B15.5%
61%
Diuretics$1.29B15.5%
60%
Others$797.05M15.5%
53%

* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans
Empower your Business
with Insights

Save over 20% on
Annual Subscription

See plans for professionals or small and medium businesses.

Wantstats analytics dashboard

Analytics

Heart Failure Drugs Market — Key Findings

Analytical insights on Heart Failure Drugs Market covering market dynamics, competitive landscape, and strategic outlook.

Key Analytical Findings

The Heart Failure Drugs Market market is projected to reach $13.07B by 2025, growing at 15.5% CAGR. The Angiotensin Receptor Neprilysin Inhibitors segment holds the largest share.

Market Dynamics

Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to the body’s need for blood and oxygen. This results in fatigue and shortness of breath and sometimes results in a cough. Due to this, everyday activities such as walking, climbing stairs, or carrying heavy weight becomes very difficult.

Factors such as rising cases of cardiovascular disorders, rising geriatric population, and the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure are driving the market growth. Additionally, a strong pipeline and product approvals are also driving the market growth. However, serious side-effects hamper the growth of the market.

Likewise, expanding drugs for heart failure with preserved ejection fraction (HF-PEF) would serve as an opportunity for growth.

Market Drivers

The heart failure drugs market has witnessed several product launches and clinical trials by major players, which would drive the growth of the heart failure drugs market. For instance,

AstraZeneca received the US Food and Drug Administration (FDA) approval for Farxiga (dapagliflozin) drug to reduce the risk of hospitalization for heart failure (hHF) in adults with type-2 diabetes (T2D) in October 2019. Ono Pharmaceutical, one of the largest pharmaceutical companies in Japan, launched Coralan (ivabradine hydrochloride), for the treatment of people with chronic heart failure (CHF), in Japan in September 2019.Amgen, in collaboration with Cytokinetics, is developing Omecamtiv mecarbil, a selective cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF).Amgen received the US Food and Drug Administration (FDA) approval in April 2015, for Corlanor (ivabradine), an oral medication indicated to reduce the risk of hospitalization for worsening heart failure in patients.

Market Opportunities

Over the years, chronic heart failure drugs have proved to be successful in slowing the progression of the disease and in reducing both mortality and morbidity in cases of heart failure with reduced ejection fraction (HF-rEF). However, heart failure with preserved ejection fraction (HFpEF) is left with no approved therapies and lies on treatment with guideline-recommended HF-REF therapies.

According to the National Center for Biotechnology Information, heart failure with preserved ejection fraction (HFpEF) is common and represents approximately 50% of the heart failure (HF) cases and is associated with high morbidity and mortality. A high number of patients affected with HFpEF serves as a lucrative opportunity for pharmaceutical companies such as Novartis, which is currently conducting late-stage trials of the Entresto drug in HFpEF patients.

This huge number of patients affected with HF-PEF, along with major manufacturers such as Novartis conducting clinical trials for heart failure with preserved ejection fraction, is likely to drive the growth global heart failure drugs market. Additionally, it will help in meeting the unmet needs of millions of patients affected with HFpEF.

Market Restraints

Despite the growing adoption of heart failure drugs, the side-effects of these drugs are hampering the market growth. Major heart failure drugs are known to cause side-effects that can affect the normal lifestyle. For instance, Entresto can cause fetal harm when administered to a pregnant woman. Pregnant women are advised to consider alternative drug treatment and discontinue Entresto. This drug also causes impaired renal function, hyperkalemia, angioedema, and hypotension.

Digoxin is known to cause nausea or vomiting, blurred or colored vision, and abnormal heart rhythm, which may cause palpitation or fainting. These side-effects are likely to hamper the growth of the heart failure drugs market.

Strategic Outlook and Future Directions

Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.

Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.

Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.

Market Value by Segment (2025)

Value (USD Mn)
Angiotensin Receptor Neprilysin Inhibitors
Angiotensin Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Beta Blockers
Diuretics
Others

Companies

Key companies profiled in Heart Failure Drugs Market

Profiles of 108 companies operating in the Heart Failure Drugs Market market, including revenue, employee count, and market positioning where available.

Showing 108 of 108 companies

BRISTOL-MY

BRISTOL-MYERS SQUIBB COMPANY

Healthcare

Company Headquarters: New York, US Founded: 1887 Workforce: ~28,000 Company Working: Bristol-Myers Squibb Company merged with Squibb in 1989. Bristol-Myers Squibb Company is a leading pharmaceutical company committed to develop and deliver innovative biopharmaceutical products to help patients fight diseases globally. It mainly focuses on six core therapeutic areas such as oncology, musculoskeletal, virology, cardiovascular, metabolomics, and immunology.

Revenue$16.6B
Employees28,000
Market CapN/A
Founded1886
New York, US
AstraZenec

AstraZeneca

Healthcare

Company Headquarters: Cambridge, UK Founded: 1999 Workforce: 83,100 Company Working: AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.

Revenue$21.0B
Employees83,100
Market CapN/A
Founded1998
Cambridge, UK
Boehringer

Boehringer Ingelheim International GmbH

Healthcare

Company Headquarters: Ingelheim am Rhein, Germany Founded: 1885 Workforce: ~50,370 Company Working: Boehringer Ingelheim International GmbH (Boehringer Ingelheim) has more than 100 years of legacy. Boehringer Ingelheim has three main business units, which include prescription medicine, animal health, and biopharma. The main focus of the company is to cure diseases with the help of its core R&D expertise. It constantly works to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies, and on science itself. Geographically it has its presence in Africa, Asia, Australasia, Europe, North America, and South America.

Revenue$15.6B
Employees50,370
Market CapN/A
Founded1884
Ingelheim am Rhein, Germany
Merck KGaA

Merck KGaA

Healthcare

Company Headquarters: Darmstadt, Germany Founded: 1668 Workforce: ~60,348 Company Working: Merck KGaA (Merck) is a pharmaceutical company that offers a varied range of products subgrouped into three segments—healthcare, life sciences, and performance materials. The company delivers innovative health solutions and is dedicated to providing breakthrough solutions and technologies. The company research drugs in the areas of oncology and neurodegenerative as well as autoimmune and inflammatory diseases. It also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for industries such as pharmaceuticals, food, cosmetics, packaging, and coatings. It has expanded its global footprint through several mergers and acquisitions, such as the acquisition of Millipore and Sigma-Aldrich. The company is distributing its products in the following countries: China, India, Japan, Australia, Israel, United Arab Emirates, South Korea, Denmark, Italy, Netherlands, Spain, United Kingdom, Switzerland, Sweden, Argentina, Brazil, Canada, US, New Zealand among others.

Revenue$21.5B
Employees60,348
Market CapN/A
Founded1667
Darmstadt, Germany
Amgen Inc.

Amgen Inc.

Healthcare

Company Overview Company Headquarters: California, US Founded: 1980 Workforce: 20,000+ Company Working: Amgen Inc. (Amgen), a well-known biopharmaceutical company, was founded in 1860. The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutic products. It uses tools such as advanced human genetics to unravel the intricacies of diseases and understand the fundamentals of human biology. It serves its products in major therapeutic areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen operates through one business segment, namely, human therapeutics. It focuses on areas that have high unmet medical needs and leverages its expertise to develop solutions for improving health outcomes and efficiently improve people's lives. It has become one of the leading independent biotechnology companies in the world.

Revenue$23.0B
Employees20,000
Market CapN/A
Founded1979
California, US
Johnson &

Johnson & Johnson Services Inc.

Healthcare

Company Headquarters: New Jersey, US Founded: 1886 Workforce: ~130,000 Company Working: Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. Ethicon has manufactured surgical sutures and wound closure devices since 1887. Ethicon manufactures sutures, endocutters, breast care products, and energy-based products, like hand instruments, for tissue dissection. In 2016, Ethicon acquired NeuWave Medical, Inc.Johnson & Johnson is the world’s largest and broadly based healthcare company. It engages in the R&D, manufacture, and sale of products in the healthcare field. I Its pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, oncology, cardiovascular and metabolism, and pulmonary hypertension t has more than 130 years of industry experience. The company has a team of 134,000 people at 260 companies in more than 60 countries around the globe.

Revenue$82.1B
Employees130,000
Market CapN/A
Founded1885
New Jersey, US
Page 1 of 18
Go to page

About the Author

Healthcare Research Team

Healthcare

Our healthcare desk at Wantstats is staffed by a mix of clinical-market analysts and a senior researcher who track drug approvals, device launches, and provider economics as they happen — not just at reporting time. Every figure in this report is checked against primary interviews, regulatory filings, and our own proprietary datasets before it goes to print.

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Heart Failure Drugs Market

Starting from
$4,950